Brian T Burger, Benjamin P Beaton, Matthew A Campbell, Benjamin T Brett, Melissa S Rohrer, Sarah Plummer, Dylan Barnes, Ke Jiang, Sudhir Naswa, Jeremy Lange, Alina Ott, Elizabeth Alger, Gonzalo Rincon, Steven Rounsley, Jeff Betthauser, Namdori R Mtango, Joshua A Benne, Jessica Hammerand, Codie J Durfee, Marisa L Rotolo, Peter Cameron, Alexandra M Lied, Matthew J Irby, David B Nyer, Chris K Fuller, Scott Gradia, Steven B Kanner, Ki-Eun Park, Jerel Waters, Sean Simpson, Bhanu P Telugu, Brianna C Salgado, Alberto Brandariz-Nuñez, Raymond R R Rowland, Matt Culbertson, Elena Rice, A Mark Cigan
{"title":"Generation of a Commercial-Scale Founder Population of Porcine Reproductive and Respiratory Syndrome Virus Resistant Pigs Using CRISPR-Cas.","authors":"Brian T Burger, Benjamin P Beaton, Matthew A Campbell, Benjamin T Brett, Melissa S Rohrer, Sarah Plummer, Dylan Barnes, Ke Jiang, Sudhir Naswa, Jeremy Lange, Alina Ott, Elizabeth Alger, Gonzalo Rincon, Steven Rounsley, Jeff Betthauser, Namdori R Mtango, Joshua A Benne, Jessica Hammerand, Codie J Durfee, Marisa L Rotolo, Peter Cameron, Alexandra M Lied, Matthew J Irby, David B Nyer, Chris K Fuller, Scott Gradia, Steven B Kanner, Ki-Eun Park, Jerel Waters, Sean Simpson, Bhanu P Telugu, Brianna C Salgado, Alberto Brandariz-Nuñez, Raymond R R Rowland, Matt Culbertson, Elena Rice, A Mark Cigan","doi":"10.1089/crispr.2023.0061","DOIUrl":null,"url":null,"abstract":"<p><p>Disease resistance genes in livestock provide health benefits to animals and opportunities for farmers to meet the growing demand for affordable, high-quality protein. Previously, researchers used gene editing to modify the porcine CD163 gene and demonstrated resistance to a harmful virus that causes porcine reproductive and respiratory syndrome (PRRS). To maximize potential benefits, this disease resistance trait needs to be present in commercially relevant breeding populations for multiplication and distribution of pigs. Toward this goal, a first-of-its-kind, scaled gene editing program was established to introduce a single modified CD163 allele into four genetically diverse, elite porcine lines. This effort produced healthy pigs that resisted PRRS virus infection as determined by macrophage and animal challenges. This founder population will be used for additional disease and trait testing, multiplication, and commercial distribution upon regulatory approval. Applying CRISPR-Cas to eliminate a viral disease represents a major step toward improving animal health.</p>","PeriodicalId":54232,"journal":{"name":"CRISPR Journal","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CRISPR Journal","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/crispr.2023.0061","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Disease resistance genes in livestock provide health benefits to animals and opportunities for farmers to meet the growing demand for affordable, high-quality protein. Previously, researchers used gene editing to modify the porcine CD163 gene and demonstrated resistance to a harmful virus that causes porcine reproductive and respiratory syndrome (PRRS). To maximize potential benefits, this disease resistance trait needs to be present in commercially relevant breeding populations for multiplication and distribution of pigs. Toward this goal, a first-of-its-kind, scaled gene editing program was established to introduce a single modified CD163 allele into four genetically diverse, elite porcine lines. This effort produced healthy pigs that resisted PRRS virus infection as determined by macrophage and animal challenges. This founder population will be used for additional disease and trait testing, multiplication, and commercial distribution upon regulatory approval. Applying CRISPR-Cas to eliminate a viral disease represents a major step toward improving animal health.
CRISPR JournalBiochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
6.30
自引率
2.70%
发文量
76
期刊介绍:
In recognition of this extraordinary scientific and technological era, Mary Ann Liebert, Inc., publishers recently announced the creation of The CRISPR Journal -- an international, multidisciplinary peer-reviewed journal publishing outstanding research on the myriad applications and underlying technology of CRISPR.
Debuting in 2018, The CRISPR Journal will be published online and in print with flexible open access options, providing a high-profile venue for groundbreaking research, as well as lively and provocative commentary, analysis, and debate. The CRISPR Journal adds an exciting and dynamic component to the Mary Ann Liebert, Inc. portfolio, which includes GEN (Genetic Engineering & Biotechnology News) and more than 80 leading peer-reviewed journals.